Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. (9th December 2021)

• Record Type: Journal Article
• Authors: Rebold, Nicholas; Morrisette, Taylor; Lagnf, Abdalhamid M; Alosaimy, Sara; Holger, Dana; Barber, Katie; Justo, Julie Ann; Antosz, Kayla; Carlson, Travis J; Frens, Jeremy J; Biagi, Mark; Kufel, Wesley D; Moore, William J; Mercuro, Nicholas; Raux, Brian R; Rybak, Michael J
• Is Part Of: Open forum infectious diseases. Volume 8:Number 12(2021)
• Publication Date: 2021-12-09
• Subjects: carbapenem-resistant Enterobacterales -- imipenem-cilastatin-relebactam -- multidrug-resistant -- Pseudomonas aeruginosa; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab554
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21, 52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.